- Conditions
- Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
- Interventions
- FOLFOX/ nal-IRI, Paclitaxel, Carboplatin, Proton Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Newton, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–66
of 66
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
- Interventions
- 5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neoplasms
- Interventions
- Liposome-encapsulated SN38
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Detroit, Michigan • Columbus, Ohio
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Liposomal irinotecan, TAS102, Bevacizumab
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma, Refractory Digestive System Neuroendocrine Carcinoma, Refractory Pancreatic Neuroendocrine Carcinoma, Unresectable Digestive System Neuroendocrine Carcinoma, Unresectable Pancreatic Neuroendocrine Carcinoma
- Interventions
- Fluorouracil, Leucovorin, Liposomal Irinotecan, Quality-of-Life Assessment
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Stony Brook, New York
- Conditions
- Advanced Small Intestine Cancer, Appendiceal Cancers
- Interventions
- Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- NALIRIFOX, Gemcitabine plus nab-Paclitaxel (GnP)
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Bay Shore, New York • Mount Kisco, New York • New Hyde Park, New York + 3 more
- Conditions
- Colorectal Cancer
- Interventions
- SN-38 liposome
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 10
- States / cities
- San Diego, California • Lewes, Delaware • Newark, Delaware + 6 more
- Conditions
- Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
- Interventions
- Pembrolizumab, Gemcitabine, Docetaxel, Nab-paclitaxel, Vinorelbine, Irinotecan, Liposomal Doxorubicin
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Goodyear, Arizona
- Conditions
- Colorectal Neoplasms
- Interventions
- CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 11
- States / cities
- Greenbrae, California • Washington D.C., District of Columbia • Coral Springs, Florida + 8 more
- Conditions
- Rhabdomyosarcoma
- Interventions
- Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2037
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
- Interventions
- CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion
- Drug
- Lead sponsor
- Famewave Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- NALIRIFOX, AD-XRT and Capecitabine
- Drug · Combination Product
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, nab paclitaxel, Onivyde, Leucovorin, 5-fu
- Drug
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pancreatic Neoplasms
- Interventions
- PEP02
- Drug
- Lead sponsor
- PharmaEngine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
- Interventions
- Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
- Drug
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pancreatic Cancer
- Interventions
- Suizenji (an ultrasound-guided HIFU therapy system), Nal-IRI/FL, mFOLFIRINOX adjuvant chemotherapy, Gem/nab-PTX
- Device · Drug
- Lead sponsor
- SONIRE Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California